This study explored the evolving landscape of Microphysiological Systems (MPS), with a focus on organoids and organ-on-a-chip (OoC) technologies, which are promising alternatives to animal testing in drug discovery. MPS technology offers in vitro models with high physiological relevance, simulating organ function for pharmacokinetic studies. Organoids composed of 3D cell aggregates and OoCs mimicking in vivo environments based on microfluidic platforms represent the forefront of MPS. This paper provides a comprehensive overview of their application in studying the gut, liver, and kidney and their challenges in becoming reliable alternatives to in vivo models. Although MPS technology is not yet fully comparable to in vivo systems, its continued development, aided by in silico, automation, and AI approaches, is anticipated to bring about further advancements. Collaboration across multiple disciplines and ongoing regulatory discussions will be crucial in driving MPS toward practical and ethical applications in biomedical research and drug development.
The small intestine and liver play important role in determining oral drug's fate. Both organs are also interconnected through enterohepatic circulation, which imply there are crosstalk through circulating factors such as signaling molecules or metabolites that may affect drug metabolism. Coculture of hepatocytes and intestinal cells have shown to increase hepatic drug metabolism, yet its crosstalk mechanism is still unclear. In this study, we aim to elucidate such crosstalk by coculturing primary human hepatocytes harvested from chimeric mouse (PXB-cells) and iPSc-derived intestinal cells in a microphysiological systems (MPS). Perfusion and direct oxygenation from the MPS were chosen and confirmed to be suitable features that enhanced PXB-cells albumin secretion, cytochrome P450 (CYP) enzymes activity while also maintaining barrier integrity of iPSc-derived intestine cells. Results from RNA-sequencing showed significant upregulation in gene ontology terms related to fatty acids metabolism in PXB-cells. One of such fatty acids, arachidonic acid, enhanced several CYP enzyme activity in similar manner as coculture. From the current evidences, it is speculated that the release of bile acids from PXB-cells acted as stimuli for iPSc-derived intestine cells to release lipoprotein which was ultimately taken by PXB-cells and enhanced CYP activity.
Microphysiological systems (MPS) incorporating microfluidic technologies offer improved physiological relevance and real-time analysis for cell-based assays, but often lack non-invasive monitoring capabilities. Addressing this gap, we developed a microfluidic cell-based assay platform integrating an electrochemical biosensor for real-time, non-invasive monitoring of kinetic cell status through glucose consumption. The platform addresses the critical limitations of traditional cell assays, which typically rely on invasive, discontinuous methods. By combining enzyme-modified platinum electrodes within a microfluidic device, our biosensor can quantify dynamic changes in glucose concentration resulting from cellular metabolism. We have integrated a calibration function that corrects sensor drift, ensuring accurate and prolonged short-term measurement stability. In the validation experiments, the system successfully monitored glucose levels continuously for 20 h, demonstrating robust sensor performance and reliable glucose concentration predictions. Furthermore, in the cell toxicity assays using HepG2 cells exposed to varying concentrations of paraquat, the platform detected changes in glucose consumption, effectively quantifying the cellular toxicity responses. This capability highlights the device’s potential for accurately assessing the dynamic physiological conditions of the cells. Overall, our integrated platform significantly enhances cell-based assays by enabling continuous, quantitative, and non-destructive analysis, positioning it as a valuable tool for future drug development and biomedical research.
Microphysiological systems (MPSs), such as organ-on-a-chip platforms, are promising alternatives to animal testing for drug development and physiological research. The BioStellar™ Plate is a commercial MPS platform featuring an open-top culture chamber design with on-chip stirrer pumps that circulate culture medium through six independent, dual microchannel-connected chamber multiorgan units. Although this design enables a circular flow, the open-top culture chamber format prevents the application of fluidic shear stress, a force that cells experience in vivo, which affects their behavior and function. To address this, we developed two fluidic shear stress attachments for the BioStellar™ Plate. These attachment channel fluids provide controlled mechanical stimulation to cultured cells. The flow dynamics were simulated using COMSOL Multiphysics to estimate shear stress levels. The attachments were fabricated and validated through fluorescent bead tracking and biological assays. The FSSA-D is designed for flat-bottom standard cell cultures, while the FSSA-I is designed for epithelial monolayers, enabling the application of fluidic shear stress across the basal membrane. Experiments with intestinal epithelial cells (Caco-2) demonstrated that both attachments enhanced cell barrier function under a fluidic environment, as indicated by higher transepithelial electrical resistance (TEER). These findings demonstrate that the attachments are practical tools for mechanobiology research with MPS platforms.
Traditional pre-clinical drug evaluation methods, including animal experiments and static cell cultures using human-derived cells, face critical limitations such as interspecies differences, ethical concerns, and poor physiological relevance. More recently, microphysiological systems (MPSs) that use microfluidic devices to mimic in vivo conditions have emerged as promising platforms. By enabling perfusion cell culture and incorporating human-derived cells, MPSs can evaluate drug efficacy and toxicity in a more human-relevant manner. However, standard MPS protocols rely on discrete medium changes, causing abrupt changes in drug concentrations that do not reflect the continuous pharmacokinetics seen in vivo. To overcome this limitation, we developed a Dialysis Membrane-integrated Microfluidic Device (DMiMD) which maintains continuous drug concentrations through selective medium change via a dialysis membrane. The membrane’s molecular weight cut-off (MWCO) enables the retention of high-molecular-weight drugs while facilitating the passage of essential low-molecular-weight nutrients such as glucose. We validated the membrane’s molecular selectivity and confirmed effective nutrient supply using cells. Additionally, anticancer drug efficacy was evaluated under continuously changing drug concentrations, demonstrating that the DMiMD successfully mimics in vivo drug exposure dynamics. These results indicate that the DMiMD offers a robust in vitro platform for accurate assessment of drug efficacy and toxicity, bridging the gap between conventional static assays and the physiological complexities of the human body.
Conventional in vitro assays and many microphysiological systems struggle to generate time-dependent drug exposure profiles because medium replacement simultaneously removes or re-adds drugs in the culture compartment. Here, we developed an Open-access Dialysis Membrane-integrated Microfluidic Device (O-DMiMD) that uses molecular weight-dependent transport across a dialysis membrane to decouple nutrient supply from drug exposure control. The device comprises a cell culture compartment (CCC) and a donor compartment (DC) separated by a dialysis membrane. Transport functions were evaluated using Lucifer Yellow, FITC-dextran, and glucose, followed by drug-response studies using SN-38 and T-DM1 under different medium change conditions. Lucifer Yellow and glucose permeated through the dialysis membrane, whereas FITC-dextran was retained. DC medium change supplied glucose to the CCC and maintained A549/HepG2 co-culture proliferation comparably to direct CCC medium replacement. For SN-38, partial transport to the DC and retention in the CCC generated time-dependent exposure profiles; in A549/HepaRG co-culture, medium change conditions altered A549 viability. For T-DM1, conditions with or without re-addition to the CCC produced different SK-BR-3 responses, suggesting exposure-dependent effects for high-molecular-weight drugs. The O-DMiMD provides an open-access in vitro platform for evaluating drug responses under exposure profiles governed by molecular weights, protein binding, medium changes, and metabolic cell contexts.